Submit Deal

ERYDEL

Summary

EryDel SpA is a global late-stage biotech company aimed at developing and commercializing therapies for the treatment of rare diseases delivered by its proprietary red blood cell technology.

Deals Overview

Total Deals1

Valued Deals1

Total Value£ 419 M

Avg. Deal Size£ 419 M

Market Context

Senior Management

Luca Benatti
CEO
Stanley Musial
CFO

Sort

erydel

HQ - Italy

Biotechnology

23 Oct 2023

Investment Date

100%

Stake

£ 419 M

Deal Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy